Oncolytic virus therapy turns one of medicine’s oldest enemies into an unlikely weapon against cancer, using specially selected or engineered viruses that infect and destroy tumor cells while leaving healthy tissue largely unharmed. The approach is not hypothetical: a modified herpes simplex virus called T-VEC has been approved for advanced melanoma, and a handful of other viral therapies have reached market in different countries. What makes the concept especially appealing is that the viruses do not just kill cancer cells directly; they also provoke the immune system into recognizing and attacking tumors it had previously ignored. The science behind all of this is more layered than a simple “virus eats cancer” story, and the field is evolving fast.
The Idea Is Older Than You Think
Doctors noticed the connection between viral infections and shrinking tumors more than a century ago. Since the mid-1800s, scattered case reports documented cancer patients whose tumors shrank during natural viral infections, a phenomenon sometimes called the “Saint Peregrine tumor” after the patron saint of cancer patients.1PubMed. History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses Most of these early cases involved blood cancers like leukemia or lymphoma, where immune suppression likely gave the virus freer rein. In one widely cited 1896 report, a woman with myelogenous leukemia went into remission after catching what was presumed to be influenza; her massively swollen liver and spleen shrank to near-normal size, and her white blood cell count dropped more than 70-fold.2Molecular Therapy. Oncolytic Viruses: The First 100 Years The remissions were real, but they were also fleeting, typically lasting only a month or two. Researchers spent much of the twentieth century trying to reproduce these effects deliberately, first with crude viral preparations and later with increasingly refined laboratory tools.
How Viruses Home In on Tumors
The central question for any cancer therapy is selectivity: how do you hit the tumor without destroying the patient? Oncolytic viruses exploit several features of cancer cells that make them unusually vulnerable to infection.
The first layer is physical entry. Viruses need specific receptors on a cell’s surface to get inside, and many tumor cells overexpress the very receptors that certain viruses use as gateways.3JAMA Oncology. Oncolytic Viruses in Cancer Treatment: A Review Researchers are also engineering viruses to recognize receptors found almost exclusively on tumor cells, narrowing the targeting even further.
The second and arguably more important layer is the antiviral defense system inside the cell. Normal cells respond to a viral invasion by ramping up interferon signaling and antiviral enzymes, creating an inhospitable environment for the virus. Many cancer cells have lost or impaired those same defense pathways, because the mutations that make cells cancerous often also disable the molecular alarms that would normally shut down viral replication. Newcastle disease virus, for example, is selectively toxic to tumor cells precisely because those cells fail to mount a proper interferon response.4PubMed Central. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy Studies have shown that tumor cells exhibit delayed and weakened activation of key antiviral enzymes compared with normal blood cells when exposed to the same virus, explaining why the virus replicates freely in tumor tissue while healthy cells fend it off.5PubMed. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
The result is a kind of biological selectivity that is hard to achieve with conventional drugs. Chemotherapy poisons all rapidly dividing cells; radiation damages everything in its beam path. An oncolytic virus preferentially enters and replicates in cells whose own defense machinery is broken, which is a reasonable working definition of a cancer cell.
Killing Cancer Two Ways at Once
The viruses fight tumors through two complementary mechanisms. The first is straightforward: the virus replicates inside a cancer cell until the cell bursts open, a process called lysis. The new viral copies then infect neighboring tumor cells, and the cycle continues.6PubMed Central. The emerging field of oncolytic virus-based cancer immunotherapy
The second mechanism is arguably more powerful. When tumor cells burst, they spill their contents into the surrounding tissue, releasing proteins and molecular signals that the immune system recognizes as danger cues. In immunology terms, the virus converts a “cold” tumor, one that has been hiding from immune surveillance, into a “hot” one that attracts and activates immune cells. Research on T-VEC in melanoma has shown that infected tumor cells release specific damage-associated molecules and that the virus recruits both virus-specific and tumor-specific killer T cells not only to the injected tumor but also to distant, uninjected tumors.7OncoImmunology. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma That distant effect, sometimes called an abscopal response, is one of the most exciting aspects of the therapy: you inject the virus into one tumor and the immune system starts attacking tumors elsewhere in the body.
Beyond the Tumor Cells Themselves
Tumors are not just clumps of cancer cells. They build their own blood supply and surround themselves with a supportive scaffold of connective tissue and immune-suppressing cells. Oncolytic viruses can disrupt this protective infrastructure. Vesicular stomatitis virus, for instance, has been shown to directly infect and destroy the blood vessels feeding a tumor while leaving normal blood vessels intact, triggering clots within tumor vessels and starving the tumor of blood flow.8PubMed Central. Targeting tumor vasculature with an oncolytic virus Vaccinia virus can also exploit the abnormal signaling in tumor blood vessels, causing vascular leakage and collapse that further undermines the tumor’s support system.9PubMed Central. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment Beyond the vasculature, accumulating evidence shows that oncolytic viruses can target the stromal components surrounding tumors, disrupting the physical and biochemical barriers that tumors use to shield themselves.10PubMed Central. Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses
Approved Therapies and What the Trials Show
The furthest along and most widely discussed oncolytic virus is talimogene laherparepvec, or T-VEC, a genetically modified herpes simplex virus approved for unresectable melanoma. In its pivotal trial of 436 patients, T-VEC produced a durable response rate of about 16%, compared with roughly 2% in the control arm, and an overall response rate of about 26%.11PubMed. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma Median overall survival was about 23 months for T-VEC patients, compared with roughly 19 months in the control group. The strongest results appeared in patients with earlier-stage disease who had not yet received other treatments. A subsequent real-world study confirmed that T-VEC monotherapy achieves high rates of complete and durable responses, and that patients with lower tumor burden tend to fare best, reinforcing the argument for using it earlier in the disease course rather than as a last resort.12PubMed Central. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load
T-VEC is not the only approved product. China approved an oncolytic adenovirus called H101 for head and neck cancer back in 2005, based on clinical trials showing good tolerability and efficacy when combined with chemotherapy.13Current Cancer Drug Targets. Clinical Trials with Oncolytic Adenovirus in China Four oncolytic viruses have now received regulatory approval worldwide, with many more in various stages of clinical trials.14PubMed Central. Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective
The Virus Toolbox
Researchers are not limited to a single virus. The field has investigated a wide range of viral platforms, each with its own strengths. Adenoviruses were among the earliest studied and remain widely used. Herpes simplex virus (the backbone of T-VEC) can carry large genetic payloads. Reovirus naturally targets cells with activated growth-signaling pathways common in many cancers. Measles virus has also been evaluated for its safety and antitumor potential.15PubMed Central. A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses Vaccinia virus, a relative of smallpox, replicates robustly in tumor tissue and has been engineered with various safety modifications. Newcastle disease virus, as discussed above, has an unusual degree of natural tumor selectivity.
Genetic engineering dramatically expands what these viruses can do. Scientists delete the viral genes that would let the virus replicate in healthy cells, add genes that code for immune-stimulating molecules, or insert genes that make the infected tumor cell produce proteins that attract the immune system. T-VEC, for instance, was engineered to produce a human immune-signaling molecule called GM-CSF that draws dendritic cells to the tumor, amplifying the immune response. The trade-off with heavy genetic modification is stability: living viruses can mutate during manufacturing, and over-engineered viruses sometimes revert toward their original form or recombine in unexpected ways, a concern that regulators take seriously.16PubMed. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses
Getting the Virus Where It Needs to Go
Delivery remains one of the field’s biggest practical challenges. T-VEC is injected directly into visible or palpable tumors, which works for accessible melanoma lesions but is impractical for cancers deep inside the body, like pancreatic or brain tumors. The alternative is intravenous delivery, where the virus travels through the bloodstream. In a mouse model of pancreatic cancer, both intratumoral and intravenous injections of Newcastle disease virus produced anti-tumor effects, and virus was detected inside tumors even after intravenous delivery, confirming that systemic spread to the tumor is possible.17PubMed Central. Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma
The catch with intravenous delivery is that the immune system treats the virus the way it treats any virus: as an invader. Antibodies, complement proteins, and immune cells in the blood can neutralize the virus before it ever reaches the tumor. Researchers are pursuing several strategies to get around this: coating viruses with protective polymers, hiding them inside carrier cells that ferry them to the tumor, and modifying the viral surface to dodge antibodies.18PubMed Central. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy One engineered vaccinia virus was specifically designed to evade neutralization by vaccinia-specific antibodies, an important step toward making repeat intravenous dosing viable.19PubMed Central. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies
Combining Viruses with Other Cancer Treatments
Oncolytic viruses are increasingly being tested alongside other therapies rather than as standalone treatments. The most promising pairing so far is with immune checkpoint inhibitors, the class of drugs (like pembrolizumab and nivolumab) that release the brakes on the immune system. A meta-analysis of clinical trials in solid tumors found that oncolytic viruses combined with checkpoint inhibitors showed better efficacy than oncolytic viruses combined with chemotherapy, with the virus-plus-pembrolizumab combination showing a particularly favorable safety and efficacy profile.20PubMed Central. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis The logic is intuitive: the virus inflames the tumor and attracts immune cells, while the checkpoint inhibitor prevents the tumor from shutting those immune cells down.
Combining oncolytic viruses with chemotherapy and radiation is trickier. In theory, chemotherapy improves the tumor’s immune environment, and radiation damages tumor DNA in ways that complement viral killing. In animal models, an interferon-expressing oncolytic adenovirus combined with chemotherapy and radiation produced synergistic effects and significant tumor growth inhibition in a pancreatic cancer model.21PubMed Central. Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer But the sequencing of these treatments is a headache. Oncolytic viruses need living tumor cells to replicate in; if chemotherapy kills most of the tumor cells first, the virus may have nowhere to grow. On the other hand, giving the virus first and then following with chemotherapy risks killing the immune cells that the virus just activated.22PubMed Central. The combination therapy of oncolytic virotherapy Getting the timing and order right is one of the most active areas of clinical research.
Why Tumors Can Resist
Not every tumor responds to oncolytic virus therapy, and understanding resistance is critical to improving outcomes. A systematic analysis found that the most commonly studied resistance mechanism is interferon-mediated defense: some tumor cells retain enough of their antiviral machinery to fend off the virus, while others do not. This creates a situation where a tumor with mixed cell populations might be only partially susceptible.23PubMed Central. Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis Beyond the cells themselves, the dense connective tissue matrix that surrounds many solid tumors can physically block viral spread. The immune system’s own efforts to clear the virus, while generally beneficial for the patient, can also limit how far the virus penetrates before being neutralized. And because tumors are genetically diverse, some cells within the same tumor may lack the surface receptors the virus needs to enter, rendering those cells invisible to the therapy.24PubMed Central. Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs
Predicting Who Will Respond
Given that responses vary widely, researchers are hunting for biomarkers that can predict which patients are most likely to benefit. For T-VEC in melanoma, one promising marker is Nectin-1, a surface protein that herpes simplex virus uses to enter cells. Studies have found that Nectin-1 expression in tumor biopsies taken before treatment significantly predicted whether the tumor would respond to T-VEC, while other markers that researchers investigated did not prove useful for prediction.25PubMed Central. Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo For a different oncolytic virus called M1, researchers have proposed a dual-biomarker approach: tumors expressing high levels of the receptor the virus uses to enter, combined with low levels of a protein that blocks viral replication, respond best.26Signal Transduction and Targeted Therapy. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors This kind of patient stratification could eventually allow oncologists to test a tumor biopsy and determine in advance whether a particular oncolytic virus is likely to work.
Safety and What Patients Experience
A reasonable concern with injecting live viruses into people is safety. The viruses used in therapy are heavily modified to eliminate their ability to cause disease in healthy tissue, but the question of whether they might spread to other organs or shed into the environment matters. Preclinical safety studies have been reassuring. In a study of an oncolytic vaccinia virus given intravenously to healthy dogs at escalating doses, the injections were well tolerated with no clinical, blood, or biochemical side effects. Viral genetic material was detected in the blood only at the earliest time point after the highest dose, and none was found in urine, saliva, or feces at any point.27Scientific Reports. Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
In human patients, the most common side effects of T-VEC are flu-like symptoms: fever, chills, and fatigue, essentially what you feel during a mild viral infection. These side effects are generally manageable and far less severe than those associated with standard chemotherapy. Injection site reactions also occur. Serious adverse events are uncommon, though as with any biological therapy, individual responses vary.
Tracking Viruses Inside the Body
One of the unique advantages of oncolytic viruses over conventional drugs is that researchers can engineer them to report their own location and activity. By inserting reporter genes into the viral genome, scientists create viruses that produce detectable signals when they are actively replicating inside a tumor. This allows noninvasive imaging to show not only where the virus has spread but how vigorously it is replicating and whether the tumor is shrinking in real time.28PubMed Central. Reporter Transgenes for Monitoring the Antitumor Efficacy of Recombinant Oncolytic Viruses
One particularly elegant system uses the sodium iodide symporter, or NIS, as a reporter gene. When expressed, NIS allows infected cells to concentrate radioactive iodine or other tracers, which can then be visualized with standard nuclear imaging equipment already available in most hospitals. Because NIS expression is directly tied to viral replication, the imaging signal reflects how actively the virus is working.29PubMed Central. The use of the NIS reporter gene for optimizing oncolytic virotherapy Reporter gene imaging can also accelerate clinical development by providing rapid, noninvasive readouts of where the virus goes after injection, how long its effects last, and how dosing changes influence the therapy.30Molecular Therapy Oncology. Oncolytic Virus Therapy: Using Viruses to Fight Cancer No conventional chemotherapy drug can tell you this kind of story about itself from inside the patient.
Manufacturing a Living Medicine
Making an oncolytic virus therapy is fundamentally different from making a pill or even a standard biologic drug. The product is a living, replicating organism, and that introduces manufacturing challenges that the pharmaceutical industry is still working through. Viral therapies must meet strict standards for purity, potency, stability, and product characterization, but the “product” can mutate over the course of production. Genetic instability is a real concern, particularly for heavily engineered viruses, which can occasionally recombine or revert toward their wild-type form during large-scale manufacturing.16PubMed. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses Scaling up production from a research lab to a facility that can supply thousands of patients requires careful process design and quality-control testing at every step. This is one of the practical bottlenecks that has slowed the broader adoption of oncolytic viruses, even when the clinical data look promising. The cost and complexity of manufacturing a living medicine at clinical grade remain substantially higher than for most small-molecule drugs, and the cold-chain storage requirements add further logistical layers for hospitals and clinics that want to offer these therapies.